Cargando…

LHRH agonists and the prevention of breast and ovarian cancer.

Early age at natural menopause or bilateral ovariectomy substantially reduce a woman's lifetime risk of breast cancer. Reversible 'bilateral ovariectomy' can now in effect be achieved by 'high-dose' luteinising hormone releasing hormone (LHRH) agonists (LHRHAs). The harmful...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pike, M. C., Ross, R. K., Lobo, R. A., Key, T. J., Potts, M., Henderson, B. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1989
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247357/ https://www.ncbi.nlm.nih.gov/pubmed/2679844

Ejemplares similares

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Subclinical leprosy manifesting as a reversal reaction after LHRH agonist administration
por: Carmo, R.L.M.L., et al.
Publicado: (2018)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

LHRH analogues in breast cancer: clever, but do we need them?
por: Smith, I. E.
Publicado: (1991)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells
por: Li, Xiaoyong, et al.
Publicado: (2016)

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
por: Emons, Günter, et al.
Publicado: (2014)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
por: McClelland, H. R., et al.
Publicado: (1992)

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer
por: Obayemi, J. D., et al.
Publicado: (2020)

Squamous cell carcinoma of the prostate following treatment with an LHRH–agonist: a rare case of transformation of adenocarcinoma of the prostate
por: Al–Qassim, Zubair, et al.
Publicado: (2014)

AB166. Recovery of spermatogenesis of KH-465 herbal extract for LHRH agonist induced male infertility in rat
por: Park, Hyun Jun, et al.
Publicado: (2015)

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer
por: Ndinguri, Margaret, et al.
Publicado: (2023)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

AB100. Recovery of spermatogenesis of KH-465 herbal extracts mixture for LHRH agonist induced male infertility in rat
por: Park, Hyun Jun, et al.
Publicado: (2016)

(99m)Tc-LHRH in tumor receptor imaging
por: Hao, Dawei, et al.
Publicado: (2017)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment
por: Ichaoui, Hamza, et al.
Publicado: (2019)

Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer.
por: Rutqvist, L. E., et al.
Publicado: (1992)

Glutaric acid as a spacer facilitates improved intracellular uptake of LHRH–SPION into human breast cancer cells
por: Kumar, Challa SSR, et al.
Publicado: (2007)

The effects of moderate physical activity on menstrual cycle patterns in adolescence: implications for breast cancer prevention.
por: Bernstein, L., et al.
Publicado: (1987)

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
por: Sciarra, Alessandro, et al.
Publicado: (2021)

Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle.
por: Mullen, P., et al.
Publicado: (1991)

From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.
por: Corbin, A.
Publicado: (1982)

Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers
por: Roy, Jyoti, et al.
Publicado: (2019)

Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2015)

On the age-dependent association between cancer of the breast and endometrium.
por: Key, T., et al.
Publicado: (1987)

Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls.
por: Bernstein, L., et al.
Publicado: (1990)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017)

Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare
por: Nasser, Nicola J., et al.
Publicado: (2022)

Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice: ANALUTS study
por: Morote, Juan, et al.
Publicado: (2022)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk
por: Lee, S A, et al.
Publicado: (2005)

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
por: He, Yingna, et al.
Publicado: (2010)

TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells
por: Liu, Lanxia, et al.
Publicado: (2014)

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma
por: Fodor, Klara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ubls11m5e3d1mlmebek4gkr84c